Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Zosano Pharma Corporation (ZSAN : NSDQ)

• Company Description    Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company's lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $2.10 Daily Weekly Monthly 20 Day Moving Average: 238,084 shares Shares Outstanding: 4.90 (millions) Market Capitalization: $10.30 (millions) Beta: 3.30 52 Week High: $37.45 52 Week Low: $1.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.41% 3.58% 12 Week -64.38% -59.96% Year To Date -87.22% -84.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 34790 ARDENTECH COURT - FREMONT,CA 94555 USA ph: 510-745-1200 fax: - zsan-ir@zosanopharma.com http://www.zosanopharma.com

• General Corporate Information    Officers Steven Lo - ChiefExecutiveOfficer Christine Matthews - Chief Financial Officer Steven A. Elms - Director Linda S. Grais - Director Kenneth R. Greathouse - Director Peer Information Zosano Pharma Corporation (CORR.) Zosano Pharma Corporation (RSPI) Zosano Pharma Corporation (CGXP) Zosano Pharma Corporation (BGEN) Zosano Pharma Corporation (GTBP) Zosano Pharma Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98979H301 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 4.90 Most Recent Split Date: 4.00 (0.03:1) Beta: 3.30 Market Capitalization: $10.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.73 Price/Cash Flow: - Price / Sales: 15.62 EPS Growth vs. Year Ago Period: -181.00% vs. Previous Quarter: -274.66% Sales Growth vs. Year Ago Period: -48.84% vs. Previous Quarter: 51.72% ROE 03/31/22 - -177.06 12/31/21 - -80.12 09/30/21 - -75.96 ROA 03/31/22 - -119.14 12/31/21 - -54.84 09/30/21 - -51.51 Current Ratio 03/31/22 - 1.61 12/31/21 - 1.04 09/30/21 - 1.56 Quick Ratio 03/31/22 - 1.61 12/31/21 - 1.04 09/30/21 - 1.56 Operating Margin 03/31/22 - -8,617.91 12/31/21 - -4,015.92 09/30/21 - -3,541.43 Net Margin 03/31/22 - -8,375.11 12/31/21 - -3,812.10 09/30/21 - -3,367.90 Pre-Tax Margin 03/31/22 - -8,375.11 12/31/21 - -3,812.10 09/30/21 - -3,367.90 Book Value 03/31/22 - 2.87 12/31/21 - 9.74 09/30/21 - 11.56 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©